Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown

Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown

Despite a late start, the American firm is bearing down on its Danish rival

The Danish giant Novo Nordisk published its quarterly results this Wednesday morning, reporting a decrease in its forecasts compared to its activity in the US market. ...

Novo Cuts Outlook, Pledges Crackdown On Copycat Obesity Drugs

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Novo Cuts Outlook, Pledges Crackdown On Copycat Obesity Drugs – altnews.org

Novo Nordisk shares surged as much as 6.5% in European trading, making it a top performer on the Stoxx 600, as

Novo Nordisk cuts forecasts as Ozempic and Wegovy sales hit by US copycat versions

Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight-loss drug Wegovy, as unauthorised compounded versions of its GLP-1 drugs eat into sales — particularly in the United States, its largest market. The Danish drugmaker, which also markets Ozempic for diabetes, now expects sales growth of 13% to 21% in constant currencies this year, down from its previous range of 16% to 24%…

Novo Cuts Outlook, Pledges Crackdown On Copycat Obesity Drugs - Nemos News Network

Novo Nordisk shares surged as much as 6.5% in European trading, making it a top performer on the Stoxx 600, as Wall Street analysts said the Danish drugmaker’s guidance cut was largely priced in—and pressures on Wegovy sales from compounded anti-obesity drugs may soon ease.  Investor sentiment was also buoyed by expectations that Wegovy sales, will rebound in the second half, as the availability of compounded copycat versions declines. “We have …